While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli Lilly ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.